Skip to search formSkip to main contentSkip to account menu

sapacitabine

Known as: 2'-C-cyano-2'-deoxy-1-arabinofuranosyl-N(4)-palmitoylcytosine, CNDAC cpd, N-(1-(2-Cyano-2-deoxy-beta-D-arabinofuranosyl)-2-oxo-1,2-dihydropyrimidin-4-yl)-hexadecanamide 
An orally bioavailable pyrimidine analogue prodrug with potential antineoplastic activity. Sapacitabine is hydrolyzed by amidases to the… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (2)

ArabinonucleosidesCytosine

Narrower (1)

CYC 682
CYC682DNAGene Expression RegulationNCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles
Background: Sapacitabine is a novel oral nucleoside analogue with a unique ability to induce single-strand DNA breaks after… 
2015
2015
Sapacitabine in the treatment of acute myeloid leukemia
Prognosis of elderly patients with acute myeloid leukemia (AML) remains poor and new treatment approaches are urgently needed. A… 
2011
2011
Novel agents for the treatment of acute myeloid leukemia in the older patient.
The incidence of acute myeloid leukemia (AML) increases with age, with a median age at diagnosis of 67 years. Older patients have… 
Review
2011
Review
2011
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
For the last twenty years, significant progress in Molecular and Cellular Biology has resulted in a better characterization and… 
2010
2010
A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.
6520 Background: Sapacitabine is an orally administered nucleoside analogue which causes single-strand DNA breaks and induces G2… 
2009
2009
A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.
Abstract 1758 Poster Board I-784 Introduction Sapacitabine is a novel nucleoside analogue with a unique ability to cause… 
Review
2008
Review
2008
Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents.
BACKGROUND Cancer control by radiotherapy (RT) can be improved with concurrent chemotherapy. Outpatient strategies for sarcomas… 
2007
2007
Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).
Background: Sapacitabine, a 2′-deoxycytidine nucleoside analogue with unique ability to cause irreparable single-strand DNA… 
2006
2006
Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Cyclacel Pharmaceuticals, under license from Sankyo Co, is developing the prodrug sapacitabine for the potential treatment of… 
1998
1998
Antitumor activity of 5'-O-dipalmitoylphosphatidyl 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine is enhanced by long-circulating liposomalization.
We previously synthesized the 5'-O-diacylphosphatidyl derivative of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)